Drug Trial Radar · NCT00249730
Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.
Last checked: Nov 19, 2026Latest source record: Feb 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
510
Actual
Start
Oct 2005
Primary completion
Not stated
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of Viagra dose titration to 100mg versus 50mg in men with erectile dysfunction, based on responses to the IIEF questionnaire as measured at the beginning and at the end of double blind treatment, comparing the group titrated to 100mg vs. the group maintained on 50mg.
Conditions
- Impotence
Interventions
SildenafilDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in IIEF erectile function domain score at the end of double blind treatment.
Locations
39 sites in 8 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Kitchener, Ontario, Canada
Pfizer Investigational Site
Sarnia, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Saint-Léonard, Quebec, Canada
Pfizer Investigational Site
Trois-Rivières, Quebec, Canada
Pfizer Investigational Site
Lille, France
Pfizer Investigational Site
Lyon, France
Pfizer Investigational Site
Montpellier, France
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Pátrai, Greece
Pfizer Investigational Site
Thessaloniki, Greece
Pfizer Investigational Site
Goudi, Athens, Greece
Pfizer Investigational Site
Beersheba, Israel
Pfizer Investigational Site
Haifa, Israel
Pfizer Investigational Site
Petah Tikva, Israel
Pfizer Investigational Site
Tel Aviv, Israel
Pfizer Investigational Site
Bologna, Italy
Pfizer Investigational Site
Florence, Italy
Pfizer Investigational Site
L’Aquila, Italy
Pfizer Investigational Site
Milan, Italy
Pfizer Investigational Site
Roma, Italy
Pfizer Investigational Site
Moscow, Russia
Pfizer Investigational Site
Alicante, Spain
Pfizer Investigational Site
Barcelona, Spain
Pfizer Investigational Site
Madrid, Spain
Pfizer Investigational Site
Málaga, Spain
Pfizer Investigational Site
Seville, Spain
Pfizer Investigational Site
Valencia, Spain
Pfizer Investigational Site
San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Pfizer Investigational Site
Bath, United Kingdom
Pfizer Investigational Site
Coventry, United Kingdom
Pfizer Investigational Site
Doncaster, United Kingdom
Pfizer Investigational Site
Dundee, United Kingdom
Pfizer Investigational Site
Glasgow, United Kingdom
Pfizer Investigational Site
Belmont, Durham, United Kingdom
Pfizer Investigational Site
Ashford, Middlesex, United Kingdom
Pfizer Investigational Site
Weybridge, Surrey, United Kingdom
Pfizer Investigational Site
Chippenham, Wilts., United Kingdom
Pfizer Investigational Site
Trowbridge, Wiltshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.